All In Biotech

Drug Trial Radar · NCT03338816

ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)

ENVISION: A Phase 3 Randomized, Double-blind, Placebo-Controlled Multicenter Study With an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients With Acute Hepatic Porphyrias

Last checked: Nov 20, 2026Latest source record: Apr 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

94

Actual

Start

Nov 16, 2017

Primary completion

Jan 31, 2019

Study completion May 31, 2021

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
First posted
Nov 9, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effect of subcutaneous givosiran (ALN-AS1), compared to placebo, on the rate of porphyria attacks in patients with Acute Hepatic Porphyrias (AHP).

Conditions

  • Acute Hepatic Porphyria
  • Acute Intermittent Porphyria
  • Porphyria, Acute Intermittent
  • Acute Porphyria
  • Hereditary Coproporphyria (HCP)
  • Variegate Porphyria (VP)
  • ALA Dehydratase Deficient Porphyria (ADP)

Interventions

  • GivosiranDrug

    Givosiran by SC

  • PlaceboDrug

    Matching placebo (normal saline \[0.9% NaCl\]) by SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Rate of Porphyria Attacks in Participants With Acute Intermittent Porphyria (AIP)Time frame: 6 months

Locations

36 sites in 18 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Little Rock, Arkansas

  • Clinical Trial Site

    San Francisco, California

  • Clinical Trial Site

    Boston, Massachusetts

  • Clinical Trial Site

    Ann Arbor, Michigan

  • Clinical Trial Site

    New York, New York

  • Clinical Trial Site

    Winston-Salem, North Carolina

  • Clinical Trial Site

    Philadelphia, Pennsylvania

  • Clinical Trial Site

    Galveston, Texas

  • Clinical Trial Site

    Salt Lake City, Utah

  • Clinical Trial Site

    Seattle, Washington

  • Clinical Trial Site

    Auchenflower, Australia

  • Clinical Trial Site

    Camperdown, Australia

  • Clinical Trial Site

    Parkville, Victoria, Australia

  • Clinical Trial Site

    Sofia, Bulgaria

  • Clinical Trial Site

    Edmonton, Canada

  • Clinical Trial Site

    Odense, Denmark

  • Clinical Trial Site

    Helsinki, Finland

  • Clinical Trial Site

    Paris, France

  • Clinical Trial Site

    Chemnitz, Germany

  • Clinical Trial Site

    Munich, Germany

  • Clinical Trial Site

    Modena, Italy

  • Clinical Trial Site

    Hamamatsu, Japan

  • Clinical Trial Site

    Iizuka, Japan

  • Clinical Trial Site

    Tokyo, Japan

  • Clinical Trial Site

    Mexico City, Mexico

  • Clinical Trial Site

    Rotterdam, Netherlands

  • Clinical Trial Site

    Warsaw, Poland

  • Clinical Trial Site

    Seoul, South Korea

  • Clinical Trial Site

    Barcelona, Spain

  • Clinical Trial Site

    El Palmar, Spain

  • Clinical Trial Site

    Pamplona, Spain

  • Clinical Trial Site

    Stockholm, Sweden

  • Clinical Trial Site

    Taichung, Taiwan

  • Clinical Trial Site

    Taipei, Taiwan

  • Clinical Trial Site

    Taoyuan City, Taiwan

  • Clinical Trial Site

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.